Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial
| Autor: | Dilshad Ahmed Khan, Aamir Ijaz, Atiq Ur Rehman Slehria, Muhammad Amjad Pervez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Complementary and Manual Therapy medicine.medical_specialty Placebo-controlled study Aspartate transaminase Placebo Gastroenterology Young Adult 03 medical and health sciences 0302 clinical medicine Insulin resistance Double-Blind Method Non-alcoholic Fatty Liver Disease Internal medicine Nonalcoholic fatty liver disease medicine Humans Vitamin E 030212 general & internal medicine Aged Advanced and Specialized Nursing biology business.industry Fatty liver Middle Aged medicine.disease Complementary and alternative medicine Alanine transaminase biology.protein Female Steatosis business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Complementary Therapies in Medicine. 52:102494 |
| ISSN: | 0965-2299 |
| DOI: | 10.1016/j.ctim.2020.102494 |
| Popis: | The aim of this study was to examine the effects of delta-tocotrienol (δ-tocotrienol) supplementation on biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).The study design was a two-group, randomized, double-blind, placebo-controlled trial. The patients with NAFLD were randomly assigned to receive δ-tocotrienol 300 mg twice daily or placebo for 24 weeks.The primary endpoints were change from baseline in fatty liver index (FLI) and homeostasis model of insulin resistance (HOMA-IR) after 24 weeks. Secondary endpoints included change from baseline in high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), alanine transaminase (ALT), aspartate transaminase (AST) and grading of hepatic steatosis on ultrasound. Between-group differences were tested for significance using ANCOVA. Mean differences (MD) with 95 % CIs are reported.A total of 71 patients (tocotrienol=35, placebo=36) were randomized and included in the intention to treat analysis. Compared with placebo, δ-tocotrienol significantly reduced (MD [95 % CI]) FLI (-8.52 [-10.7, -6.3]; p0.001); HOMA-IR (-0.37 [-0.53, -0.21]; p0.001), hs-CRP (-0.61[-0.81, -0.42]; p0.001), MDA (-0.91 [-1.20, -0.63]; p0.001), ALT (-8.86 [-11.5, -6.2]; p0.001) and AST (-6.6 [-10.0, -3.08]; p0.001). Hepatic steatosis was also reduced by a significantly greater extent with tocotrienol than with placebo (p =0.047). No adverse events were reported.δ-tocotrienol effectively improved biochemical markers of hepatocellular injury and steatosis in patients with NAFLD. δ-tocotrienol supplementation might be considered as a therapeutic option in the management of patients with NAFLD.Sri Lankan Clinical Trials Registry (SLCTR/2015/023, 2015-10-03). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect